Estradiol increases cAMP in the oviductal secretory cells through a nongenomic mechanism

María L. Oroítica1,2, John Lopez1,2, Israel Rojas1,2, Jocelyn Rocco1,2, Patricia Díaz1,2, Patricia Reuquén1,2, Hugo Cardenas1,2, Alexis Parada-Bustamante3 and Pedro A. Orihuela1,2

1Laboratorio de Inmunología de la Reproducción, Facultad de Química y Biología, Universidad de Santiago de Chile, Alameda 3363, Casilla 40, Correo 33, Santiago, Chile, 2Centro para el Desarrollo en Nanociencia y Nanotecnología-CEDENNA, Santiago, Chile and 3Instituto de Investigaciones Materno-Infantil, Universidad de Chile, Santiago, Chile

Correspondence should be addressed to P A Orihuela; Email: pedro.orihuela@usach.cl

Abstract

In the rat oviduct, estradiol (E2) accelerates egg transport by a nongenomic action that requires previous conversion of E2 to methoxyestradiols via catechol-O-methyltransferase (COMT) and activation of estrogen receptor (ER) with subsequent production of cAMP and inositol triphosphate (IP3). However, the role of the different oviductal cellular phenotypes on this E2 nongenomic pathway remains undetermined. The aim of this study was to investigate the effect of E2 on the levels of cAMP and IP3 in primary cultures of secretory and smooth muscle cells from rat oviducts and determine the mechanism by which E2 increases cAMP in the secretory cells.

In the secretory cells, E2 increased cAMP but not IP3, while in the smooth muscle cells E2 decreased cAMP and increased IP3. Suppression of protein synthesis by actinomycin D did not prevent the E2-induced cAMP increase, but this was blocked by the ER antagonist ICI 182 780 and the inhibitors of COMT OR 486, G protein-α inhibitory (Gαi) protein pertussis toxin and adenylyl cyclase (AC) SQ 22536. Expression of the mRNA for the enzymes that metabolizes estrogens, Comt, Cyp1a1, and Cyp1b1 was found in the secretory cells, but this was not affected by E2. Finally, confocal immunofluorescence analysis showed that E2 induced colocalization between ESR1 (ERα) and Gαi in extranuclear regions of the secretory cells. We conclude that E2 differentially regulates cAMP and IP3 in the secretory and smooth muscle cells of the rat oviduct. In the secretory cells, E2 increases cAMP via a nongenomic action that requires activation of COMT and ER, coupling between ESR1 and Gαi, and stimulation of AC.


Introduction

In the female genital tract, estrogens regulate a variety of biological functions including gamete transport, oocyte fertilization, embryo development, and implantation (reviewed in Croxatto (1996)). The classical mechanism by which estradiol (E2) affects its target cells comprises binding to estrogen receptors (ERs) and modification of gene expression and protein synthesis (Nilsson et al. 2001). However, this model cannot explain E2 effects that are not blocked by inhibitors of transcription or translation, or that are too rapid to be due to changes in gene expression. These features do not appear compatible with the classical genomic actions and are termed nongenomic (Lössel & Wheling 2003, Lössel et al. 2003). Nongenomic actions of E2 often involve activation of G protein-α inhibitory (Gαi), stimulation of intracellular signal transduction pathways that include generation of second messengers such as cAMP and inositol triphosphate (IP3), and activation of protein kinase A (PKA) or phospholipase C (PLC) in the E2-target cells (Nadal et al. 2001, Wyckoff et al. 2001, Acconcia et al. 2005, Hill et al. 2010). Recently, it has been also proposed that estrogen metabolites could be responsible for some E2 nongenomic actions (Mueck & Seeger 2010, Rincón-Rodríguez et al. 2013).

In the rat, the duration of oviductal egg transport is dependent on ovarian hormones and mating-associated signals (for review see Croxatto (2002)). A single injection of E2 on day 1 of the cycle or pregnancy shortens oviductal transport of eggs from the normal 72–96 to <24 h (Ortíz et al. 1979). We have previously demonstrated that RNA and protein synthesis inhibitors did not block E2-induced acceleration of oviductal egg transport in unmated rats, indicating that E2 accelerates oviductal egg transport by a nongenomic mechanism (Orihuela et al. 2001). This E2 nongenomic pathway involves a previous conversion of E2 to methoxyestradiols, mediated by the enzyme catechol-O-methyltransferase (COMT; Parada-Bustamante et al. 2007, 2010), activation of ER and adenyl cyclase (AC) (Orihuela et al. 2003), and successive production of cAMP and IP3 (Orihuela et al. 2003, 2006, 2013).
The rat oviduct is a tubular organ mainly composed of an intrinsic layer smooth muscle fiber, the myosalpinx, and an innermost highly folded mucosa (secretory, ciliated, and stromal cells), the endosalpinx. From the ovary to the uterus, it is possible to distinguish in the oviduct the fimbria, the ampulla, the isthmus, and the utero-tubal junction. In the ampulla, ciliated cells are more abundant whereas in the isthmus secretory cells are predominant (Croxatto 1996). Transport of oocytes through the ampulla depends on the contractile activity of the smooth muscle cells (Moore & Croxatto 1988a, Rios et al. 2007). The actual vision on the mechanics involved in the secretory and smooth muscles cells in the E2 nongenomic signaling that accelerates egg transport in the rat oviduct. Therefore in this work, we examined the contribution of the secretory cells initiating waves of myosalpinx (mainly composed of smooth muscle cells) contractions that lead to increase in the speed of the egg transport (Moore & Croxatto 1988b, Croxatto 2002, Parada-Bustamante et al. 2012). Therefore in this work, we examined the contribution of the secretory and smooth muscles cells in the E2 nongenomic signaling that accelerates egg transport in the rat oviduct. First, we determined the effect of E2 on the levels of cAMP or IP3 in the secretory and smooth muscle cells from rat oviducts. The results oriented us to investigate the mechanism by which E2 increases cAMP in the secretory cells. Thus, we examined the effect of E2 on the cAMP level in the secretory cells under conditions in which protein synthesis, ER, COMT, Gαs, or AC activity was quenched by selective inhibitors. In addition, the effect of E2 on the expression of some enzymes involved in estrogen metabolism and colocalization between ESR1 (ERα) and the Gαs protein was determined in the oviductal secretory cells.

Materials and methods

Animals

Locally bred Sprague–Dawley rats weighing 200–260 g were used. The animals were kept under controlled temperature (21–24 °C), and lights were on from 0700 to 2100 h. Water and pelleted rat chows were supplied ad libitum. Female mature rats were used in the estrus stage. The phases of the estrous cycle were determined by daily vaginal smears (Turner 1961) and all females were used after showing two consecutive 4-day cycles. The care and manipulation of the animals was done in accordance with the ethical guidelines of the Universidad de Santiago de Chile.

Culture of primary cells from rat oviducts

Secretory cells

A protocol to obtain secretory cells instead of ciliated cells was performed in this work (Morales et al. 2000, 2006). For each replicate, 12 oviducts from six rats were excised and placed in pre-warmed Hanks’ solution (Sigma Chemical Co.) of pH 7.4. The whole oviduct was cut into small (4–8 mm²) pieces in Hanks’ solution and then the epithelial cells were mechanically removed from the rest of the tissue. The cell suspension was centrifuged at 800 g during 5 min, washed, and seeded into six-well tissue culture plates coated with collagen I, rat-tail (Invitrogen) in DMEM/high modified medium with 4.0 mM L-glutamine and 4.500 mg/l glucose free of Phenol Red (cat. no. SH30284.02, HyClone, Thermo Scientific, Walthman, MA, USA) supplemented with 10% (V/V) of fetal bovine serum (Cat. No. SH30396.03, HyClone), sodium pyruvate 1 mM, and antibiotics: 100 UI/ml of penicillin and 100 μg/ml of streptomycin. The epithelial cells were incubated at 37 °C in an atmosphere of 5% (vol/vol) CO₂ for at least 3 days to 75–80% confluence and characterized by immunofluorescence staining with a cytokeratin antibody. The presence of secretory and ciliated cells in the primary cultures was determined using immunohistochemical staining for MUC1 (secretory cell marker; DeSouza et al. 1998) and β-tubulin IV (ciliated cell marker; Shao et al. 2007, Nutu et al. 2009).

Smooth muscle cells

For each replicate, 12 oviducts from six rats were excised and places in pre-warmed Hanks’ solution (Sigma Chemical Co.) of pH7.4. The whole oviduct was cut into small (4–8 mm²) pieces in Hanks’ solution and then the smooth muscle cells were mechanically removed from the rest of the tissue and treated with collagenase, type I (Invitrogen) for 1 h to further the disaggregation of the cells. The cell suspension was centrifuged at 1200 g during 5 min, washed, and seeded into six-well tissue culture plates (Becton Dickinson & Co., Franklin Lakes, NJ, USA) in DMEM/high modified medium with 4.0 mM L-glutamine and 4.500 mg/l glucose free of Phenol Red (cat. no. SH30284.02, HyClone, Thermo Scientific) supplemented with 10% (vol/vol) of fetal bovine serum (cat. no. SH30396.03, HyClone), sodium pyruvate 1 mM, and antibiotics: 100 UI/ml of penicillin and 100 μg/ml of streptomycin. Smooth muscle cells were incubated at 37 °C in an atmosphere of 5% (vol/vol) CO₂ for at least 7 days to reach 75–80% confluence and characterized by immunohistochemical staining with an α-actin antibody.

Treatments

Primary cultures of secretory and smooth muscle cells were treated with 10⁻³ M of E2 (Sigma) or ethanol 0.01% as vehicle. Other primary cultures of secretory cells were also incubated with the protein synthesis inhibitor actinomycin D (ActD, 1 μg/μl, Sigma), the ER antagonist ICI 182 780 (25 μg/μl, Tocris Bioscience, Bristol, UK), the AC inhibitor SQ 22536 (7.5 μg/ml, Calbiochem, La Jolla, CA, USA), the selective COMT activity inhibitor OR 486 (25 μg/ml, Tocris Bioscience), or the Gαs protein inhibitor pertussis toxin (PTX, 1 μg/μl) as appropriate to each experiment. DMSO 0.01% was used as a vehicle of the inhibitors as it is more efficient than ethanol to dissolve nonpolar or semi-polar drugs.

Measurement of cAMP levels

The primary cell cultures were sonicated in 100 μl of ice cold 10% (v/v) trichloroacetic acid (TCA) and centrifuged for 15 min
at 5000 g at 4 °C. The pellet was discarded and the supernatant was washed four times with five volumes of water-saturated diethyl ether. The upper layer was discarded after each wash. Following the last wash, the aqueous extract was dried under a stream of nitrogen at 60 °C. The levels of cAMP in dried extracts were determined using Biotrak cAMP enzyme immunoassay system, cat. no. RPN 225 (Amersham Pharmacia Biotech). This kit is based on competition unlabeled cAMP and a fixed quantity of peroxidase-labeled cAMP for a limited number of binding sites on a cAMP-specific antibody. This allows the construction of a standard curve and the measurement of cAMP levels in unknown samples. 3,3',5,5'-tetramethylbenzidine/hydrogen peroxide was used as a substrate for color development. The optical density was read at 630 nm using a microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).

Measurement of IP3 levels

The primary cell cultures were sonicated in 100 µl of ice-cold 1 M TCA and centrifuged for 10 min at 1000 g at 4 °C. The pellet was discarded and the supernatant was incubated for 15 min at room temperature. TCA was removed from the supernatant with 0.5 ml of a solution 1,1,2-trichloro-trifluoro-ethane (Sigma Chemical Co.)–triocylamine (Sigma), 3:1 (v/v). The levels of IP3 were determined using the Inositol-1,4,5-trisphosphate [3H] Radioreceptor Assay Kit, cat. no. NEK064 (NEN Life Science Products, Boston, MA, USA). This kit is based on a competition between non-radioactive IP3 and a fixed quantity of [3H]-IP3 for a limited number of cation cerebellum IP3 receptor-binding sites. This allows the construction of a standard curve and the measurement of IP3 levels in unknown samples.

Real-time PCR

Total RNA from primary secretory cell cultures was isolated using TRIzol Reagent (Invitrogen). One microgram of total RNA of each sample was treated with DNase I, amplification grade (Invitrogen). The SYBR Green I double-strand DNA binding dye (Roche Diagnostics GmbH) was used to quantify the relative gene expression of Comt, Cyp1a1, and Cyp1b1 in the oviducal secretory cells; Gapdh was chosen as the housekeeping gene for load control. The SYBR Green I double-strand DNA binding dye (Roche Diagnostics) was the reagent of choice for these assays. Primers for Comt, 5'-CAC GCA CTG CAC ACA GAA GGA GG-3' (sense) and 5'-GTT AGT GTG TGC ACT CGA AGC-3' (antisense); Cyp1a1, 5'-AGT TTC GGG GAG GTT ACT GTT TC-3' (sense) and 5'-GGA CAT ACA AGA CAG CCT CAT T-3' (antisense); Cyp1b1, 5'-CTT GGA CTC TCA GGT TG-3' (sense) and 5'-CCA TTC TTT CGC TAC TCG TCT CGG-3'; and Gapdh, 5'-ACC ACA GTC CAT GCC ATC AC-3' (sense) and 5'-TCC ACC ACC CTG TGT CAT GA-3' (anti sense). All real-time PCR assays were carried out in duplicate. The thermal cycling conditions included an initial activation step at 95 °C for 25 min, followed by 40 cycles of denaturing and annealing-elongation (95 °C for 15 s, 59 °C for 30 s, and 72 °C for 30 s), and finally one cycle of melting (95–60°C). To verify specificity of the product, amplified products were subject to melting curve analysis as well as electrophoresis, and product sequencing was carried out to confirm identity using an ABI Prism310 Sequencer. The expression of Comt, Cyp1a1, and Cyp1b1 was determined using the equation: \[ Y = 2^{-\Delta C_p} \] where Y is the relative expression, \( C_p \) (crossing point) is the cycle in the amplification reaction in which fluorescence begins to be exponential above the background base line, \( -\Delta C_p \) is the result of subtracting \( C_p \) value of Cyp1a1, Cyp1b1, and Comt from \( C_p \) value of Gapdh for each sample. To simplify the presentation of the data, the relative expression values were multiplied by 10^\( b \) (Livak & Schmittgen 2001).

Immunofluorescence

Oviducal cells were fixed in cold 4% paraformaldehyde in PBS of pH 7.4–7.6 for 2 h, transferred to 10% w/v sucrose in PBS for 60 min at 4 °C and 30% w/v sucrose in PBS at 4 °C overnight. Then, they were blocked with 1% PBS–BSA for 120 min and incubated with mouse anti-cytokeratin (Santa Cruz Biotechnology, Inc.) or mouse anti-z-actin (Santa Cruz Biotechnology, Inc.) antibody 1:250 and 1:500 respectively. After washing with PBS, the preparations were incubated for 2 h with rabbit anti-mouse IgG FITC conjugate (Santa Cruz Biotechnology, Inc.) diluted 1:1000. The sections were washed and counterstained with 1 µg/ml of Hoechst 33342 (Thermo Scientific, Rockford, IL, USA), washed again and then mounted in Fluoromount G. As negative controls, the primary antibody was replaced by preimmune serum. All sections were visualized under an Optiphot Epifluorescence Microscope (Olympus).

Immunohistochemical

Oviducal cells were fixed in cold 4% paraformaldehyde in PBS of pH 7.4–7.6 for 2 h, transferred to 10% w/v sucrose in PBS for 60 min at 4 °C and 30% w/v sucrose in PBS at 4 °C overnight. Then, they were blocked with 1% PBS–BSA for 120 min and incubated with rabbit anti-MUC1 (Abcam, Cambridge, MA, USA) or mouse anti-b-tubulin IV (Sigma) antibody 1:100. After washing with PBS, the preparations were incubated for 2 h with goat anti-rabbit IgG FITC conjugate (Chemicon International, Temecula, CA, USA) or mouse anti-cytokeratin (Chemicon International, Temecula, CA, USA). The alkaline phosphatase activity was detected by color development during incubation of the cells in 100 mM Tris/HCl of pH 9.5, 100 mM NaCl, and 5 mM MgCl2, containing BCIP/NBT tablets (Sigma Chemical Co.; one tablet in 10 ml). As negative controls, the primary antibody was replaced by preimmune serum. All sections were visualized under an phase-contrast Optiphot Epifluorescence Microscope (Olympus).

Confocal microscopy

Oviducal cells were fixed in cold 4% paraformaldehyde in PBS of pH 7.4–7.6 for 2 h and transferred to 10% w/v sucrose in PBS for 60 min at 4 °C and 30% w/v sucrose in PBS at 4 °C via free access
www.reproduction-online.org

Estradiol’s nongenomic action on the cAMP level 287


Downloaded from Bioscientifica.com at 04/25/2022 10:14:23 PM
via free access
overnight. Then, they were blocked with 1% PBS–BSA for 120 min and incubated with rabbit anti-ESR1 (Santa Cruz Biotechnology, Inc.) or mouse anti-αgi (Santa Cruz Biotechnology, Inc.) antibody 1:50 in 1% PBS–BSA in a humidified chamber overnight. Followed by three rinses in PBS, the cells were incubated for 60 min at room temperature with secondary antibody Alexa Fluor 555-conjugated goat anti-rabbit IgG (Invitrogen) or Alexa Fluor 588-conjugated goat anti-mouse IgG (Invitrogen) diluted in 1% PBS–BSA. The samples were subsequently washed with PBS and mounted in DABCO (Sigma). As negative controls, the primary antibody was replaced by preimmune serum. All sections were visualized with laser scanning confocal microscopy on a Axiovert 100 M microscope (Carl Zeiss, Jena, Germany).

**Statistical analysis**

Data for cAMP and IP3 assays or real-time PCR from cultured oviductal cells were replicated five times for each treatment (for each culture experiment, oviductal cells were recovered from a pool of six different rats). Results subjected to statistical analysis were expressed as mean ± S.E.M. Data were subjected to Kruskal–Wallis test, followed by Mann–Whitney U test for pairwise comparisons when overall significance was detected. Significance was accepted at \( P \leq 0.05 \).

**Results**

**E2 differentially regulates cAMP and IP3 levels in secretory and smooth muscle cells of the rat oviduct**

This experiment was designed to determine the effect of E2 on the level of cAMP and IP3 in the oviductal secretory and smooth muscle cells. First, we confirmed the purity of the cells by immunofluorescence staining of cytokeratin or α-actin (Fig. 1) and also established that the primary cultures of the epithelial cells were conforming by secretory cells (Fig. 2). Therefore, secretory or smooth muscle cells were treated with ethanol or E2 during 0, 1, 3, or 6 h and processed to measure the concentration of cAMP or IP3 as described in the ‘Materials and methods’ section. Replicas of this experiment are indicated in Figs 3 and 4.

Figure 3 shows that in the secretory cells, the basal cAMP level ranged from 48.1 ± 21.1 to 63.0 ± 19.5 fmol/µg of protein and in the smooth muscle cells it ranged from 25.8 ± 5.9 to 32.4 ± 6.9 fmol/µg of protein. In the secretory cells, treatment with E2 increased threefold the amount of cAMP at 3 and 6 h but not at 1 h. In the smooth muscle cells, E2 decreased threefold the amount of cAMP level at 3 h with no effect at 1 and 6 h. On the other hand, Fig. 4 shows that E2 did not affect the basal level of IP3 in the secretory cells (vehicle, 134 ± 45–164 ± 53 fmol/µg of protein and E2, 93 ± 55–117 ± 044 fmol/µg of protein) while in the smooth muscle cells E2 increased IP3 level to fourfold at 6 h (vehicle, 150 ± 60 fmol/µg of protein and E2, 800 ± 130 fmol/µg of protein) without any effect at 1 h (vehicle, 190 ± 70 fmol/µg of protein and E2, 140 ± 90 fmol/µg of protein) and 3 h (vehicle, 130 ± 70 fmol/µg of protein and E2, 104 ± 90 fmol/µg of protein).

**Figure 1** Expression of cytokeratin and α-actin in the primary cultures of epithelial and smooth muscle cells from rat oviducts. Representative photomicrographs of primary cultures of epithelial and smooth muscle cells from rat oviducts were processed by immunofluorescence microscopy to detect the expression of cytokeratin and α-actin. Note that cytokeratin (green) and α-actin (green) were only expressed in epithelial and smooth muscle cells respectively. Nuclei were stained with Hoechst 33342 (blue). Negative controls of the immunoreactivity were incubated with preimmune serum.

**Figure 2** Primary cultures of epithelial cells from rat oviducts express MUC1 but not β-tubulin IV. Representative photomicrographs of primary cultures of epithelial cells from rat oviducts were processed by immunohistochemistry to detect the expression of MUC1 (marker for secretory cells) and β-tubulin IV (marker of ciliated cells). Note that positive immunoreactivity for MUC1 (purple) was only observed in the epithelial cells. Negative controls of the immunoreactivity were incubated with preimmune serum.
E2 increased cAMP level by a nongenomic action in the oviductal secretory cells

These experiments were carried out to determine whether the effect of E2 on the cAMP level in the oviductal secretory cells is mediated by activation of ER, Gαi, and AC. For this, we used ICI 182 780 that is an ER antagonist, PTX that is a highly specific inhibitor of heteromeric G proteins of the Gα class and SQ 22536 that is a selective inhibitor of AC activity. In each experiment, primary cultures of secretory cells from rat oviducts were divided into the following treatment groups: i) ethanol + DMSO, ii) E2 + DMSO, iii) ethanol + inhibitor, and iv) E2 + inhibitor. At 3 h after treatment, the cultured cells were processed to measure the concentration of cAMP as described in the ‘Materials and methods’ section. Replicas of this experiment are indicated in Fig. 6.

The results are shown in Fig. 6. In the control group, the cAMP level ranged from 51.1 ± 10.3 to 55.6 ± 17.1 pmol/µg of protein while in the E2-treated group it ranged from 283.3 ± 19.7 to 316.9 ± 51.3 fmol/µg of protein. Administration of ICI 182 780, PTX, or SQ 22536 alone did not affect the basal cAMP level (range, 46.8 ± 19.2–64.2 ± 14.1 fmol/µg of protein) although

**E2 increased cAMP level through activation of ER, Gαi, and AC in the oviductal secretory cells**

This experiment was designed to determine whether the effect of E2 on the cAMP level in the secretory cells occurs under conditions in which RNA and protein synthesis is suppressed. For this we used ActD, which is an inhibitor of RNA and protein synthesis. Primary cultures of secretory and smooth muscle cells from rat oviducts were divided into the following treatment groups: i) ethanol + DMSO, ii) E2 + DMSO, iii) ethanol + ActD, and iv) E2 + ActD. At 3 h after treatment, cultured cells were processed to measure the concentration of cAMP as described in the ‘Materials and methods’ section. Replicas of this experiment are indicated in Fig. 5.

In the control group, the cAMP level was 58.3 ± 10.1 fmol/µg of protein, while in the E2-treated group it was 283.9 ± 16.7 fmol/µg of protein. Administration of ActD alone or concomitant with E2 neither affected the basal cAMP level (49.6 ± 12.3 fmol/µg of protein) nor the E2-induced cAMP increase (230.3 ± 22.9 fmol/µg of protein) in the oviductal secretory cells.

Figure 3 Effect of E2 on the cAMP level in primary cultures of secretory and smooth muscle cells from rat oviducts. Primary cultures of secretory and smooth muscle cells from rat oviducts were treated with E2 10⁻⁹ M and 0, 1, 3, or 6 h later the cAMP level was determined by an enzyme immunoassay system. Note that in the epithelial cells, E2 increased the cAMP level 3 and 6 h after treatment, while in the smooth muscle cells E2 decreased the cAMP level 6 h after treatment. This experiment consisted of five replicates. a ≠ b, P<0.05.

Figure 4 Effect of E2 on the IP3 level in primary cultures of secretory and smooth muscle cells from rat oviducts. Primary cultures of secretory and smooth muscle cells from rat oviducts were treated with E2 10⁻⁹ M and 0, 1, 3, or 6 h later the IP3 level was determined by a radioreceptor assay. Note that in the epithelial cells, E2 did not affect the IP3 level while in the smooth muscle cells E2 increased the IP3 level 6 h after treatment. This experiment consisted of five replicates. a ≠ b, P<0.05.
E2 increased cAMP level through activation of COMT in the oviductal secretory cells

In this study, we investigated whether the effect of E2 on the level of cAMP in the secretory cells occurs under condition in which COMT activity is suppressed. For this we used OR 486 which is a selective inhibitor of the COMT activity. Primary cultures of secretory cells from rat oviducts were divided into the following treatment groups: i) ethanol + DMSO; ii) E2 + DMSO; iii) ethanol + OR, 486; and iv) E2 + OR 486. At 3 h after treatment, the cultured cells were processed to measure the concentration of cAMP as described in the ‘Materials and methods’ section. Replicas of this experiment are indicated in Fig. 7A.

Figure 7A shows that in the control group, the cAMP level was 68.3 ± 14.1 pmol/µg of protein, while in the E2-treated group treated it was 243.9 ± 36.7 fmol/µg of protein. Administration of OR 486 alone did not affect the basal cAMP level (71.8 ± 23.4) although blocked the E2-stimulated cAMP increase (69.5 ± 19.4).

E2 did not change the expression of the Comt, Cyp1a1, and Cyp1b1 transcripts in the oviductal secretory cells

As COMT and the cytochrome P450 isofoms CYP1A1 and CYP1B1 convert E2 into methoxyestradiols, we determined the effect of E2 on the mRNA levels for Comt, Cyp1a1, and Cyp1b1. Primary cultures of oviductal secretory cells were treated with ethanol or E2 10⁻⁹ M and 3 h later the mRNA level for these enzymes was assessed by real-time PCR. Replicas of this experiment are indicated in Fig. 7B. E2 treatment did not change the mRNA level of Comt, Cyp1a1, and Cyp1b1 in the oviductal secretory cells (Fig. 7B).

E2 induced colocalization between ESR1 and Gαi in the oviductal secretory cells

In this study, we examined whether E2 is able to induce colocalization between ESR1 and Gαi in the oviductal secretory cells. Primary cultures from rat oviductal secretory cells were treated with ethanol or E2 10⁻⁹ M and 3 h later the expression and colocalization of ESR1 and Gαi were assessed by confocal microscopy. This experiment was replicated five times.

Figure 5 Effect of actinomycin D (ActD) on the E2-induced cAMP increase in the oviductal secretory cells. Primary cultures of secretory cells from rat oviducts were treated with E2 10⁻⁹ M alone or with the protein synthesis inhibitor ActD 1 µg/µl and 3 h later the cAMP level was determined by an enzyme immunoassay system. Note that ActD did not block the effect of E2 on the cAMP level. This experiment consisted of five replicates. a ≠ b, P<0.05.

Figure 6 Effect of ICI 182 780, PTX, or SQ 22536 on the E2-induced cAMP increase in the oviductal secretory cells. Primary cultures of secretory cells from rat oviducts were treated with E2 10⁻⁹ M alone or with the estrogen receptor antagonist ICI 182 780 25 µg/ml, the Gαi protein inhibitor PTX 25 µg/ml, or the adenylyl cyclase inhibitor SQ 22536 7.5 µg/ml and 3 h later the cAMP level was determined by an enzyme immunoassay system. Note that all three inhibitors blocked the effect of E2 on the level of cAMP. This experiment consisted of five replicates. a ≠ b, P<0.05.
production between 3 and 6 h, although the response of
IP3 was not affected. In the smooth muscle cells, E2
transiently decreased cAMP level at 3 h while IP3 level
was increased at 6 h. Thus, E2 differentially regulates
cAMP and IP3 production in the secretory and smooth
muscle cells of the rat oviduct. These differences may be
attributed to the differential expression of the ER
subtypes that exist in the secretory and smooth muscle
cells of the rat oviduct (Mowa & Iwanaga 2000, Orihuela
et al. 2009) or to changes in the different pools of ER that
initiate E2 nongenomic actions between these two
cellular phenotypes (Orihuela et al. 2009).

Further investigation to disclose the signaling pathway
by which E2 increases the level of cAMP in the secretory
cells of the rat oviduct revealed that this effect of E2 was
by a nongenomic mechanism because suppression of
mRNA protein synthesis by ActD did not prevent the
effect of E2 on the cAMP level. Blockade of ER by ICI
182 780 and inhibition of AC by SQ 22536 suppressed
the E2-induced cAMP increase in the secretory cells of
the rat oviduct indicating that the E2 nongenomic
pathway that increases cAMP requires binding of the
hormone to its classical receptor and activation of AC.
Several works have implicated to the E2 nongenomic
actions with the intracellular cAMP-signaling cascade.
E2 activates AC in vascular smooth muscle, breast
cancer, and uterine cells by a nongenomic mechanism
(Aronica et al. 1994, Farhat et al. 1996), while acute
stimulation of Ca2+ uptake induced by E2 is accom-
panied by increased cAMP content in rat duodenal cells
and preosteoclastic cells (Fiorelli et al. 1996, Picotto
et al. 1996). Our findings provide the first evidence of a
nongenomic action of E2 associated to a cAMP increase
in the secretory cells of the mammalian oviduct.
Probably, this E2 nongenomic action could be associated
to the regulation of the secretory activity necessary to

Discussion

The E2 nongenomic pathway that accelerates egg
transport involves sequential activation of the signaling
cascades of cAMP–PKA–PLC–IP3 in the rat oviduct
(reviewed in Orihuela et al. (2013)). However, the role
of the different cell phenotypes of the rat oviduct on this
E2 nongenomic pathway is still unknown. Herein, we
show for the first time the separate contributions of the
secretory and smooth muscle cells on the dynamic
process that modulates cAMP and IP3 levels in response
to an E2 pulse. In the secretory cells, E2 increased cAMP

www.reproduction-online.org

Figure 8 Estradiol induces colocalization between ESR1 and Gαi in the
oviductal secretory cells. Representative photomicrographs obtained
from primary cultures of oviductal secretory cells treated with E2
10^{-9} M or vehicle and 3 h later the colocalization between ESR1
(green) and Gαi (red) were determined by confocal microscopy. The
merged image display colocalization of ESR1 and Gαi as an orange
signal (arrows) only in the group treated with E2. Magnification is
shown in the inset.
accelerate egg transport in the rat oviduct. Alternatively, regulation of the tubal fluid formation by an increase in the level of cAMP may be useful in providing an adequate environment for some reproductive events as sperm migration, oocyte fertilization, or preimplantation embryo development. According with this assumption, previous works have reported that estrogens regulate the formation of tubal fluid secreted by the oviductal epithelial cells (Leese et al. 2001) and that cAMP increases fluid secretion into the oviductal lumen of several species (Leung et al. 1995, Chen et al. 2010, Liao et al. 2013).

There is increasing evidence that some biological effects of E2 are in part mediated by its metabolites 2- and 4-methoxyestradiol (Mueck & Seeger 2010, Parada-Bustamante et al. 2013, Perez-Sepulveda et al. 2013), indicating an important role of methoxyestrogens in the signaling cascades of E2 on its target organs. Our results showing that suppression of the COMT activity blocked the E2-stimulated cAMP accumulation in the secretory cells of the rat oviduct suggest that this nongenomic action of E2 requires previous conversion of E2 to methoxyestrogens. Furthermore, the enzymes necessary to metabolize estrogens are present in the oviductal secretory cells, although their expression was not regulated by E2. In order to corroborate the importance of methoxyestrogens in the nongenomic action of E2 that increases cAMP in the oviductal secretory cells, it is necessary to treat these cells with methoxyestrogens and evaluate their effects on the level of cAMP; however, this was not explored in this work.

The role of G proteins in the nongenomic actions of E2 has been documented in a variety of cell types (Levin 1999, Fu & Simoncini 2008). In this context, we have found that the ADP-ribosylating agent PTX blocked the effect of E2 on the cAMP production in the secretory cells, indicating a requirement for heterotrimeric Gtype proteins in this nongenomic action of E2. This is supported by the fact that E2 also induced colocalization between ESR1 and Gαi in non-nuclear sites of these cells, suggesting coupling of ESR1 with Gαi protein as a requisite for the E2-induced cAMP increase. Although all major subclass of G proteins are expressed in many cell types, it appears that Gαi subclass is in a great mode, the one most often linked with the E2 nongenomic actions involving the participation of a presumptive ESR1 localized in extranuclear sites (Wyckoff et al. 2001, Kumar et al. 2007, Lin et al. 2011, Watson et al. 2012). To our knowledge, this is the first report showing association between ESR1 and Gαi in extranuclear sites of the epithelium cells that may mediate an E2 nongenomic action in the mammalian oviduct. On the other hand, we cannot assure whether this ESR1–Gαi colocalization occurs in the plasma membrane or is a consequence of diminution of the ESR1 or Gαi expression in the secretory cells, because subcellular fractionation or immunoprecipitation experiments were not done in this work. Further studies are necessary to disclose the molecular and cellular mechanisms that explain how the activation of the Gαi protein participates in the E2 nongenomic pathway of the rat oviduct.

E2 regulates the expression of insulin-like growth factor 1 (IGF1), IGF1-binding proteins, and IGF1 receptors in neurons of the CNS and in reproductive tissues (Wimalasena et al. 1993, Sahlin et al. 1994, Azcoitia et al. 1999). Furthermore, IGF1 stimulates the accumulation of cAMP in mouse astrocytes and in the preoptic area and hypothalamus of the rat. Moreover, IGF1 is able to induce activation of ER via an increase in intracellular cAMP level in the rat uterine cells (Aronica & Katzenellenbogen 1993, Bartella et al. 2012). Probably, the E2-induced cAMP increase observed in the secretory cells of the rat oviduct involves functional cross talk between E2/ER and IGF1 signaling pathways, but this remains undetermined.

In summary, we have found that E2 differentially regulates cAMP and IP3 production in the secretory and smooth muscle cells of the rat oviduct. In the secretory cells, E2 increases cAMP production by a nongenomic action that requires COMT and ER activation, coupling between ESR1 and Gαi, and stimulation of AC. These findings provide new evidence for understanding the contribution of the different cellular phenotypes present in the rat oviduct on the nongenomic regulation of the egg transport exerted by E2.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work received financial support from grants FONDECYT no. 1110662 and Proyecto BASAL FBO-07.

References


Aronica SM & Katzenellenbogen BS 1993 Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 7 743–752.


Adrenomedullin increased the short-circuit current in the pig oviduct on day 1 of pregnancy mimic the transport of native ova.

Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism.


Mating effects on female reproductive conditions. In Functional cross-talk after activation of P2 and P1 receptors in oviducal ciliated cells. American Journal of Physiology 279 C658–C669.

Estradiol's nongenomic action on the cAMP level.

Hoechst 33342 and calcium ions but not by nitric oxide.

Estradiol accelerates oviductal egg transport in cyclic rats.

Moles are important factors associated to physiological and physiopathological conditions. In Estradiol: Synthesis, Health and Drug Interactions.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.

Estradiol's nongenomic action on the cAMP level.


Received 4 March 2014
First decision 9 April 2014
Revised manuscript received 14 May 2014
Accepted 11 June 2014